Johnson & Johnson (NYSE:JNJ) Shares Sold by Sterling Investment Counsel LLC

Sterling Investment Counsel LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 11.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,735 shares of the company’s stock after selling 628 shares during the period. Sterling Investment Counsel LLC’s holdings in Johnson & Johnson were worth $742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in JNJ. Hibernia Wealth Partners LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $27,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC increased its position in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC increased its holdings in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after purchasing an additional 86 shares during the period. Finally, VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $48,000. 68.40% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $155.23 on Friday. The company has a market capitalization of $374.07 billion, a P/E ratio of 11.24, a P/E/G ratio of 2.61 and a beta of 0.53. The business’s 50 day moving average is $159.00 and its two-hundred day moving average is $156.79. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.35 earnings per share. Analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were given a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $167.00 to $180.00 in a report on Friday, December 1st. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $177.31.

Check Out Our Latest Stock Analysis on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.